NovaBay Pharmaceuticals to Present at the Virtual Sequire Biotechnology Conference on February 2, 2023
January 31 2023 - 5:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces
that Justin Hall, CEO, will present a company overview at the
virtual Sequire Biotechnology Conference on Thursday, February 2 at
2:30 p.m. Eastern time. To register for the event, visit the
Sequire Biotechnology website.
“We closed 2022 with one of our best quarters ever for Avenova®
unit sales. Looking into 2023, we are increasing our focus on our
safe, effective wound care products, which we expect will become an
important contributor to our business,” said Mr. Hall. “We are
excited to share an update on our opportunities with investors
attending this conference.”
An archived webcast of the presentation will be available on the
NovaBay website. NovaBay will report 2022 fourth quarter and full
year financial results on March 23, 2023.
About Sequire
Sequire is a premier investor intelligence and communications
platform where companies can track their investors’ behaviors and
trends and use those insights to engage current and potential
investors across marketing channels. More information is available
at srax.com and mysequire.com.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 OTC
dermatologist-developed skincare products through the DERMAdoctor
website, well-known traditional and digital beauty retailers, and
international distributors. NovaBay also manufactures and sells
effective, yet gentle and non-irritating wound care products. The
PhaseOne® brand is distributed through commercial partners in the
U.S. for professional use only, and the NeutroPhase® brand is
distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook Follow us on Twitter Connect with NovaBay on
LinkedIn Visit NovaBay’s Website
Avenova Purchasing Information For NovaBay Avenova
purchasing information: Please call 800-890-0329 or email
sales@avenova.com Avenova.com
DERMAdoctor Purchasing Information For DERMAdoctor
purchasing information: Please call 877-337-6237 or email
service@dermadoctor.com DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230131005342/en/
NovaBay Contact Justin Hall Chief Executive Officer and
General Counsel 510-899-8800 jhall@novabay.com
Investor Contact LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024